1. South Korea Stocks

  2. •

    Electronic technology

  3. •

    Semiconductors
VIVOZON PHARMACEUTICAL CO., LTD.

VIVOZON PHARMACEUTICAL CO., LTD.

KKRX:082800
2,900.00
KRW
-70.00
(-2.36%)
-649.35EPS
194.03BMarket Cap
VIVOZON PHARMACEUTICAL CO., LTD.
KRX:082800
(Korea Stock Exchange)

Recent

price

2,900.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
7,625.81
6,487.73
15,695.36
17,822.71
14,774.48
11,136.32
8,462.6
6,798.83
3,838.69
2,011.58
1,564.57
1,659.89
1,115.72
1,405.42
1,724.78
1,127.3
1,043.94
Revenue per Share
-858.07
-1,289.26
144.52
-338.53
-159.86
-1,203.67
-220.99
-742.89
-712.14
-1,252.88
-1,570.41
-2,002.97
-863.46
-66.15
-196.54
-615.94
-650.94
Basic EPS, GAAP
-9,104.27
-132.15
155.08
-71.09
-317.91
97.86
503.5
-179.74
-510.97
-189.31
123.03
-851.97
-258.93
-72.49
-94.63
-172.52
-356.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5,489.87
3,671.25
3,813.4
4,386.01
4,201.22
3,055.51
2,818.61
1,995.31
4,322.04
4,255.45
3,603.74
2,355.53
2,078.58
2,073.04
2,026.75
1,391.9
1,624.49
Book Value per Share
4,464.92
3,559.07
3,727.7
4,072.21
3,637.84
2,529.46
2,436.55
1,704.58
4,284.93
4,248.18
2,040.37
2,037.49
1,897.56
1,857.1
1,797.2
1,039.41
1,324.78
Tangible Book Value per Share
7
7
7
8
8
8
8
9
12
22
28
35
46
51
51
53
53
Basic Weighted Avg Shares
55,585
47,382
117,695
133,948
119,989
89,739
68,211
61,021
46,003
44,953
43,592
57,560
51,564
71,318
87,601
59,343
54,864
Sales/Revenue/Turnover
-9.37
-6.72
7.36
3.08
-2.49
-9.48
0.72
-8.2
-28.06
-4.39
-18.22
-30.57
-10.38
6.6
3.26
-32.3
-35.87
Operating Margin (%)
11,476
5,697
5,766
4,735
5,629
5,426
3,498
3,321
2,459
2,117
2,179
5,552
3,643
3,228
3,564
4,427
4,616
Depreciation Expense
-6,255
-9,416
1,084
-2,544
-1,298
-9,699
-1,781
-6,668
-8,534
-27,998
-43,754
-69,457
-39,906
-3,357
-9,982
-32,424
-34,210
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-11.25
-19.87
0.92
-1.9
-1.08
-10.81
-2.61
-10.93
-18.55
-62.28
-100.37
-120.67
-77.39
-4.71
-11.39
-54.64
-62.35
Profit Margin (%)
10,315
9,349
24,752
16,974
21,439
12,875
15,007
8,020
40,709
91,122
10,834
7,310
-31,699
-19,640
-27,804
-44,173
-16,670
Working Capital
49,460
8,808
15,000
2,889
3,556
3,000
2,063
- -
21,744
7
15,979
14,644
1,481
994
842
534
366
LT Debt
56,150
26,812
27,851
35,389
33,898
24,654
22,742
16,100
68,446
108,997
111,560
86,542
103,466
104,067
106,427
72,665
97,737
Total Equity
- -
- -
17.47
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-14.79
-28.15
3.97
-8.05
-3.75
-33.13
-7.52
-34.33
-20.19
-31.56
-40.36
-72
-42.32
-3.24
-9.48
-36.21
-34.26
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
38,894
41,807
35,793
LT Borrowings
- -
- -
- -
LT Finance Leases
274
534
366
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
53
52
60
Market Capitalization
327,522
198,822
194,030

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
33,472
33,539
41,176
Cash, Cash Equivalents & STI
5,208
5,158
16,175
Accounts Receivable, Net
- -
9,739
- -
Inventories
18,777
15,849
14,434
Total Current Liabilities
68,362
77,712
57,846
Payables & Accruals
- -
- -
- -
ST Debt
38,894
41,807
35,793
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.8%
-6.35%
-31.72%
Free Cash Flow
-62.85%
-194.2%
88.96%
Net Income, GAAP
85.18%
69.36%
224.83%
Sales/Revenue/Turnover
-1.4%
10.1%
-32.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,854
20,867
23,631
23,250
87,601
2025
18,585
17,802
6,758
16,198
59,343
2026
14,106
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-19.75
-10.34
4.7
-171.76
-196.54
2025
-71.47
-80.17
-220.95
-242.64
-615.94
2026
-106.6
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
NVIDIA Corporation (NASDAQ:NVDA)
Micron Technology, Inc. (NASDAQ:MU)
Advanced Micro Devices, Inc. (NASDAQ:AMD)
Intel Corporation (NASDAQ:INTC)
Broadcom Inc. (NASDAQ:AVGO)
Marvell Technology, Inc. (NASDAQ:MRVL)
Business
Vivozon Pharmaceutical Co., Ltd. is a South Korea-based pharmaceutical and healthcare company engaged in the research, development, manufacturing, and commercialization of ethical prescription drugs, over-the-counter medications, health functional foods, derma-cosmetics, and proprietary non-opioid pain therapeutics. Founded in 2000 and headquartered in Seoul, South Korea, with major production and research facilities in Hwaseong, Gyeonggi-do, the company operates across pharmaceutical, consumer health, and contract manufacturing segments to serve healthcare providers, pharmacies, and commercial partners domestically and internationally. Its extensive product and service portfolio includes ethical and over-the-counter pharmaceuticals spanning circulatory and cardiovascular treatments; central nervous system and psychiatric therapeutics; gastrointestinal and metabolic agents; respiratory and antihistaminic drugs; anti-inflammatory, analgesic, and musculoskeletal remedies; antimicrobial and dermatological formulations; health functional nutritional supplements and vitamins; specialized skincare and medical cosmetic lines; and contract development and manufacturing organization (CDMO) services encompassing oral solid dosage forms, liquid preparations, and topical ointments. In clinical development, the company develops non-narcotic, non-NSAID analgesics led by its flagship compound Opiranserin (VVZ-149) for acute postoperative pain and VVZ-2471 for neuropathic pain and substance use disorders. In recent major corporate developments, the company completed its organizational integration and rebranding following its strategic acquisition by the Vivozon Group, modernized and scaled its manufacturing infrastructure to strengthen Good Manufacturing Practice compliance, advanced the regulatory approval submission and commercial launch preparations with the Korean Ministry of Food and Drug Safety for Opiranserin injectable formulations following successful Phase 3 trials, entered strategic domestic distribution and co-promotion agreements to expand hospital network penetration, and launched new functional consumer healthcare and aesthetic skincare product lines to diversify its revenue streams.